CDT EQUITY INC. Debt Conversion, Original Debt, Amount
CDT EQUITY INC. (CDT) reported Debt Conversion, Original Debt, Amount of $1.50 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionOriginalDebtAmount1 · last filed 2023-03-28
- CDT EQUITY INC. debt conversion, original debt, amount for the quarter ending 2022-12-31 was $350.00K.
- CDT EQUITY INC. debt conversion, original debt, amount for the quarter ending 2022-09-30 was $0.00.
- CDT EQUITY INC. debt conversion, original debt, amount for the quarter ending 2022-06-30 was $0.00.
- CDT EQUITY INC. debt conversion, original debt, amount for the quarter ending 2022-03-31 was $1.15M.
- CDT EQUITY INC. debt conversion, original debt, amount for fiscal 2022 was $1.50M.
| Period end | Debt Conversion, Original Debt, Amount 2 month | Debt Conversion, Original Debt, Amount 3 month | Debt Conversion, Original Debt, Amount 6 month | Debt Conversion, Original Debt, Amount 9 month | Debt Conversion, Original Debt, Amount 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | $350.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $350.00K derived: sum of 2 quarters · filed 2023-03-28 | $350.00K derived: sum of 3 quarters · filed 2023-03-28 | $1.50M 10-K · filed 2023-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $1.15M 10-Q · filed 2022-11-07 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.15M 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $1.15M 10-Q · filed 2022-05-18 | ||||
| 2021-12-31 | $1.15M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |